Document Detail

Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
MedLine Citation:
PMID:  23211038     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Fingolimod and natalizumab have the same European Union licence for the treatment of relapsing multiple sclerosis, and are considered by the Committee for Medicinal Products for Human Use (CHMP) to have broadly similar efficacy.
OBJECTIVE: A cost-minimization analysis was performed to compare differences in treatment costs between fingolimod and natalizumab from a societal perspective in Sweden.
METHODS: This analysis included costs associated with initiating and following treatment (physician visits and monitoring), continuing therapy (drugs and administration), and lost patient productivity and leisure time. Unit costs (in Swedish krona [SEK]) were based on regional data (median prices for physician visits and monitoring sessions). Natalizumab infusion costs were obtained from the national cost-per-patient database. Drug costs for both therapies were 15,651 SEK/28 days.
RESULTS: After 3 years, fingolimod use was associated with savings of 124,823 SEK/patient compared with natalizumab (total cost/patient: 566,718 SEK vs 691,542 SEK). Cost savings with fingolimod were 40,402 SEK/patient after 1 year and 301,730 SEK/patient after 10 years. Treatment with natalizumab was 18% more expensive than fingolimod therapy after 1 year and 23% more expensive after 10 years.
LIMITATIONS: Based on the CHMP assessment, it was assumed that fingolimod and natalizumab have similar efficacy. The analysis was conducted for Sweden, and caution is needed in extrapolating the results to other countries.
CONCLUSION: Fingolimod is cost-saving compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
Niklas Bergvall; Magnus Tambour; Freddie Henriksson; Sten Fredrikson
Related Documents :
2310738 - A cephalometric study to compare the effects of cervical traction and andresen therapy ...
12608728 - The effects of activator treatment on the craniofacial structures of class ii division ...
19358388 - Treatment classification of class iii malocclusion.
20122438 - Miniscrews in orthodontic treatment: review and analysis of published clinical trials.
23633778 - A comparative evaluation of the effectiveness of subpedicle acellular dermal matrix all...
16839968 - The all-in-one nutrient solution in parenteral nutrition.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-12-18
Journal Detail:
Title:  Journal of medical economics     Volume:  16     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2013  
Date Detail:
Created Date:  2013-02-13     Completed Date:  2013-08-07     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  England    
Other Details:
Languages:  eng     Pagination:  349-57     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / economics*,  therapeutic use
Cost of Illness
Costs and Cost Analysis / methods
Immunosuppressive Agents / economics*,  therapeutic use
Medication Adherence
Multiple Sclerosis, Relapsing-Remitting / drug therapy*,  mortality
Propylene Glycols / economics*,  therapeutic use
Sphingosine / analogs & derivatives*,  economics,  therapeutic use
Sweden / epidemiology
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Immunosuppressive Agents; 0/Propylene Glycols; 0/natalizumab; 3QN8BYN5QF/fingolimod; NGZ37HRE42/Sphingosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to en...
Next Document:  Aptamer-conjugated multifunctional nanoflowers as a platform for targeting, capture, and detection i...